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Abstract
Introduction: Although	the	clinical	manifestations	of	severe	haemophilia	A	(HA)	are	
well	studied,	the	challenges,	if	any,	of	living	with	mild	HA	are	not	clearly	delineated	
to date.
Aim: To	assess	available	evidence	of	clinical	risks	and	societal/economic	impacts	of	
disease	in	adult	patients	with	mild	HA	using	a	systematic	literature	review.
Methods: Prespecified	study	selection	criteria	were	applied	in	a	comprehensive	lit‐
erature	search.	Included	studies	varied	in	design	and	reported	outcomes	of	interest	
for	adults	(≥13	years	of	age)	with	mild	HA.
Results: Seventeen	studies	with	a	total	of	3213	patients	met	eligibility	criteria	(pub‐
lished	or	presented	in	English,	1966‐2017).	Most	studies	were	observational,	and	the	
outcomes	reported	were	too	sparse	and	dissimilar	to	support	a	formal	meta‐analysis.	
Mean	annual	bleeding	rates	ranged	from	0.44	to	4.5	episodes	per	patient	per	year.	
Quality	of	life	(QoL;	SF‐36	General	Health)	was	impacted	compared	to	healthy	con‐
trols.	Health	care	costs	and	productivity	were	seldom	assessed	and	no	robust	com‐
parisons	to	healthy	controls	were	available.
Conclusion: Quantifying	outcomes	for	adult	patients	with	mild	HA	remains	challeng‐
ing,	with	 estimates	 of	 key	QoL	 and	 cost	 data	 often	 based	on	 small	 data	 sets	 and	
without	comparison	to	population	norms.	Therefore,	the	clinical	impact	of	mild	hae‐
mophilia	may	be	under‐represented	and	unmet	needs	may	remain	unaddressed.	As	
paradigm‐changing	 therapies	 for	HA	emerge,	 stronger	 knowledge	of	mild	HA	 can	
guide	the	development	of	care	options	that	minimize	burden	and	enhance	the	QoL	
for	this	segment	of	the	haemophilia	community,	and	for	the	haemophilia	community	
in totality.
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1  | INTRODUC TION
Haemophilia	 A	 (HA)	 is	 an	 X‐linked	 bleeding	 disorder	 caused	 by	
a	 deficiency	 of	 blood	 coagulation	 factor	 VIII	 (FVIII),	 occurring	 in	
approximately	1	out	of	every	5000	male	 live	births.1	HA	can	be	a	
life‐threatening	 condition	 that	 requires	 lifelong	monitoring	 and/or	
treatment.	 Management	 strategies	 include	 the	 use	 of	 plasma‐de‐
rived	 or	 recombinant	 factor	 concentrates	 and	 can	 vary	 between	
treatment	centres	and	disease	severity.2
Factor	VIII	replacement	therapy,	however,	is	not	without	risk	(eg	the	
development	of	inhibitors)	and	is	expensive,	ranging	from	$50	000	to	
nearly	$300	000	annually	in	a	recent	US	study,	depending	on	disease	
severity	and	treatment	approach.3	Severity	levels	for	HA	have	generally	
been	defined	by	baseline	FVIII	activity:	severe	<1%	of	normal	or	<1	IU/
dL,	moderate	1%	to	<5%	and	mild	5%‐40%.4	The	clinical	manifestations	
and	cost	impacts	of	severe	HA	are	well	studied,	particularly	with	regard	
to	the	clinical	benefit,	but	high	cost,	of	ongoing	FVIII	prophylaxis.2,5,6
In	contrast,	the	clinical	burden,	societal	impact	and	economic	im‐
pact	of	mild	HA	are	not	as	clearly	understood.	Patients	with	mild	HA	
often	require	and	receive	less	intense	therapy	and	medical	attention,	
but	may	still	experience	 limitations	 in	daily	activities	and	 impacts	of	
the	 disease	 on	 their	morbidity,	 quality	 of	 life	 (QoL)	 and	 health	 care	
utilization.7,8	It	 is	also	unclear	to	what	extent	variations	in	treatment	
strategies,	patient	characteristics	and	geographic	location	are	associ‐
ated	with	clinical	outcomes	and	potential	delay	in	diagnosis	and	treat‐
ment.	In	this	study,	we	sought	out	published	estimates	of	the	burden	
of	mild	HA	from	clinical,	patient,	payer	and/or	societal	perspectives.
2  | MATERIAL S AND METHODS
This	 systematic	 literature	 review	 was	 performed	 using	 recom‐
mended	best	practices,	including	a	prespecified	protocol	defining	
the	search	strategy,	inclusion	criteria	and	statistical	analysis	plan	
addressing	the	burden	of	disease	and	clinical	risks	associated	with	
mild	HA	 in	 adults.	 This	 review	was	 conducted	 and	 reported	 ac‐
cording	 to	PRISMA	guidelines.9	The	protocol	 for	 the	 review	was	
agreed	to	 in	advance	by	all	authors	but	was	not	submitted	to	an	
external	registry.
The	population	of	interest	was	adults	(defined	as	being	13	years	
of	age	or	older)	with	mild	HA.	We	were	unable	 to	 find	any	 recent	
summary	of	the	literature	in	this	population,	and	the	clinical	picture	
may	 be	 distinct	 from	 both	moderate/severe	HA	 and	mild	 haemo‐
philia	B.	Because	we	anticipated	small	numbers	of	studies	focused	
exclusively	on	mild	HA	adults	over	18	years	of	age,	we	included	stud‐
ies	of	mild	HA	individuals	13	years	of	age	and	older.	Studies	of	any	
design	(interventional	or	observational,	controlled	or	uncontrolled)	
were	eligible	so	long	as	they	reported	data	for	at	 least	10	patients	
in	the	population	of	interest.	This	lower	limit	of	10	patients	was	pro‐
spectively	defined	 in	order	 to	exclude	 studies	of	 insufficient	 sam‐
ple	size,	for	which	outcomes	may	not	be	generalizable	as	they	may	
focus	on	 reports	 of	 unusual	 cases.	Outcomes	of	 interest	 included	
bleeding	events	(any	event	as	defined	or	described	by	authors),	QoL,	
joint	pain,	function/disability,	health	care	utilization	and	cost	(direct	
health	 care	 cost	 and/or	 indirect	 societal	 cost).	As	our	 goal	was	 to	
assess	the	burden	of	disease,	no	specific	intervention	or	comparison	
was	required	in	the	included	studies.
2.1 | Data sources and search strategies
A	comprehensive	search	of	English‐language	biomedical	literature	was	
conducted.	We	 searched	 electronic	 repositories	 including	 PubMed/
MEDLINE,	the	Cochrane	Library	and	EMBASE	for	all	available	dates	
up	to	the	search	cut‐off	date	of	31	December	2017.	The	search	terms	
used	 for	 each	 database	 are	 detailed	 in	Appendix	 S1.	 In	 addition	 to	
published	journal	articles,	recent	haematology	meetings	(2016‐2017)	
were	searched	for	abstract	presentations	of	eligible	studies	which	may	
not	yet	have	been	published	in	full.	Finally,	we	hand‐searched	the	ref‐
erence	lists	of	eligible	articles	and	recent	reviews.
2.2 | Study selection
Two	 levels	of	screening	were	performed	on	all	non‐duplicate	cita‐
tions	downloaded	 from	 the	 search	and	each	 level	of	 screening	 in‐
volved	up	to	two	reviewers.	Level	I	screening	was	conducted	on	the	
title	and	abstract	of	each	citation	to	identify	potentially	eligible	stud‐
ies,	 including	haemophilia	populations	with	mixed	severity.	 Level	 I	
screening	was	performed	by	a	single	 reviewer,	with	any	questions	
resolved	by	consultation	with	a	second	reviewer.	Level	II	screening	
was	conducted	as	defined	in	the	protocol,	by	reviewing	the	full	text	
of	each	article	to	 identify	eligible	studies	that	fit	with	study	selec‐
tion	criteria.	Level	II	screening	was	conducted	by	one	reviewer	and	
verified	by	a	second	reviewer.	A	published	study	would	be	included	
in	our	analysis	and	moved	forward	for	data	extraction	only	if	both	
reviewers	 in	the	Level	 II	screening	agreed	that	study	selection	cri‐
teria were met.
Per	predefined	exclusion	criteria,	meeting	abstracts	or	presen‐
tations	 prior	 to	 2016,	white	 papers,	 publications	with	 no	 primary	
data,	animal	or	in	vitro	studies,	studies	exclusively	in	FVIII	inhibitor	
patients	or	paediatric	patients	(age	<13	years),	and	studies	of	mixed/
unspecified	haemophilia	populations,	with	data	not	separable	by	dis‐
ease	severity,	were	excluded.
2.3 | Data collection and outcomes
For	the	purposes	of	this	assessment,	mild	HA	is	defined	by	FVIII	levels	
of	5%‐40%	and	adults	are	defined	as	being	13	years	of	age	and	older.	
Where	data	were	available	for	a	subset	of	patients	meeting	this	defini‐
tion,	we	included	the	article	and	extracted	data	only	for	the	subset	of	
interest.	Studies	without	at	least	one	outcome	separately	reported	for	
at	least	10	patients	of	interest	were	excluded.	The	primary	endpoint	
was	 the	 rate	of	bleeding	events,	on	a	mean	episodes	per	year	basis	
or	any	other	units	reported	by	authors.	We	summarized	all	events	re‐
ported	by	authors,	regardless	of	whether	bleeds	required	treatment,	
and	captured	the	definition	of	bleeding	events	if	reported.	As	mild	HA	
patients	tend	to	bleed	less	frequently	and	typically	only	after	trauma,	
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to	fully	characterize	the	clinical,	patient‐reported	and	societal	burden	
of	mild	HA,	additional	outcomes	were	captured.	Secondary	outcomes	
included	QoL;	joint	pain;	function/disability,	including	productivity	and	
employment;	other	morbidity	or	mortality	attributed	to	HA;	and	health	
care	utilization	and	cost.
Dual	review	was	used	to	collect	data	from	each	eligible	study	using	
a	standardized	template.	Any	discrepancies	in	interpretation	between	
the	two	reviewers	were	resolved	through	a	discussion	of	the	text	of	the	
original	articles.	Each	included	study	was	appraised	for	quality	and	risk	
of	bias	using	the	Oxford	Center	for	Evidence‐Based	Medicine	(Oxford	
CEBM)	Levels	of	Evidence.10	 Industry	 sponsorship	was	captured	 for	
each	included	study,	based	on	author	disclosures	or	affiliations.
2.4 | Synthesis of results
We	 planned	 to	 conduct	 a	meta‐analysis	 if	 sufficient	 comparable	 data	
were	found	for	a	primary	or	secondary	outcome.	Differences	in	author	
definitions	of	 the	primary	 endpoint,	 the	 rate	of	 bleeding	 events,	were	
available.	These	were	captured	and	reviewed	for	comparability	(eg	only	
bleeds	 requiring	 treatment,	only	 spontaneous	bleeds	unrelated	 to	 sur‐
gical	 or	 dental	 procedures,	 any	bleeding	 event).	Where	data	were	 too	
sparse	or	too	heterogeneous	to	be	combined	across	studies,	descriptive	
statistics	were	performed	 in	order	 to	qualitatively	 summarize	available	
evidence.	The	risk	of	bias	across	studies	was	assessed	informally	based	on	
study	design,	level	of	evidence,	size,	and	representativeness	of	the	popu‐
lation	of	interest,	and	comparability	of	estimates	from	different	studies.
3  | RESULTS
3.1 | Study selection
The	search	 identified	1845	unique	citations	across	all	sources.	After	
screening	of	 the	 titles	and	abstracts,	139	potentially	eligible	studies	
were	obtained	 in	 full	 text	 for	 review	 (Figure	1).	Application	of	eligi‐
bility	 criteria	 resulted	 in	 17	 included	 studies,	 comprising	 20	 pub‐
lications	 due	 to	 separate	 reports	 on	 the	 same	or	 overlapping	 study	
populations.3,8,11‐28	The	primary	reasons	for	study	exclusion	were	that	
patients	 with	 haemophilia	 were	 not	 separated	 by	 severity	 (or	 only	
moderate/severe	 HA	 patients	 were	 included),	 or	 study	 populations	
were	mixed	with	regard	to	type	of	haemophilia	(A/B/other	coagulopa‐
thies)	and/or	age	(adults	and	children).	In	addition,	14	studies	did	not	
report	an	outcome	of	interest	and	20	studies	were	reviews,	case	re‐
ports	or	studies	not	containing	at	least	10	mild	HA	patients.
3.2 | Study characteristics
The	17	studies	included	data	for	3213	mild	HA	patients	aged	13	years	
and	older.	These	patients	were	a	subset	of	the	overall	study	popula‐
tion	 in	all	 cases.	The	 total	number	of	haemophilia	patients	 (all	 ages,	
severities	 and	 types)	 in	 the	 17	 studies	was	 20	587.	 Eligible	 studies	
were	conducted	in	Europe	(59%),	North	America	(35%)	and	Japan	(6%)	
(Table	1).	Most	studies	were	observational	in	nature,	and	few	details	
on	typical	treatment	protocols	were	available.	A	variety	of	treatments	
were	described	by	authors,	including	FVIII	concentrates,	recombinant	
FVIII	and	DDAVP.	Fewer	than	1%	of	patients	had	prophylactic	use	of	
FVIII,11,13,27	except	 in	one	study	 reported	as	a	meeting	abstract,	 for	
which	long‐term	use	of	FVIII	concentrate	was	required.18
3.3 | Risk of bias
Most	evidence	was	Oxford	Level	of	Evidence	 IB	or	 IIB,	 consisting	
of	prospective	or	retrospective	cohort	studies,	in	many	cases	from	
a	 single	 centre	 (Table	 1).	No	 randomized	 controlled	 trials	meeting	
inclusion	 criteria	 were	 identified.	 The	 risk	 of	 selective	 reporting/
outcome	availability	bias	was	high,	as	mild	HA	adults	were	typically	
a	subset	of	the	entire	study	population,	and	not	all	outcomes	were	
F I G U R E  1  Study	attrition
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available	 for	 this	 subset.	 Seven	 studies	 were	 industry‐sponsored.	
No	differences	in	outcomes	were	apparent	between	industry‐spon‐
sored	and	non‐industry‐sponsored	studies;	no	formal	meta‐analysis	
or	assessment	of	publication	bias	was	conducted.
3.4 | Clinical burden: bleeding events
Clinical	burden	of	mild	HA	was	reported	in	a	variety	of	formats	in	the	
included	studies.	We	sought	data	on	annual	bleeding	rates	(ABR)	or	
other	characterizations	of	bleeding	risk.	Most	often,	bleeding	events	
were	reported	as	a	percentage	of	patients	with	any	bleeding	episode	
over	a	period	of	time	(cumulative	incidence),	with	both	follow‐up	du‐
ration	and	the	definition	of	events	varying	between	studies	(Table	2).	
One	multicentre,	prospective	 study	 from	 the	US	 reported	a	mean	
ABR	of	4.5	±	10.0	episodes/year	in	23	mild	HA	adult	patients3; how‐
ever,	other	estimates	were	lower	by	an	order	of	magnitude.8,25	Most	
studies	meeting	inclusion	criteria	did	not	report	mean	ABR.
Bleeding	 events	 in	 mild	 HA,	 such	 as	 joint	 bleeds	 or	 cerebral	
bleeds,	 may	 not	 be	 readily	 apparent.	 One	 study	 used	 cerebral	
MRI	 to	 assess	mild	HA	adults	with	no	prior	 symptomatic	 cerebral	
bleeding;	5.5%	(1/18)	of	patients	had	evidence	of	a	previous	cerebral	
microbleed.27
3.5 | Other morbidity
Joint	 pain	 and	 damage	 resulting	 from	 subclinical	 joint	 bleeds	may	
also	be	problematic	in	mild	HA.	Joint	score	data,	like	data	for	bleed‐
ing	 events,	 were	 not	 reported	 in	 a	 standard	 way	 across	 studies	
(Table	3).	In	a	small	cross‐sectional	survey	study	from	1996,	20%	of	
mild	HA	patients	age	16	or	older	experienced	moderate	or	severe	
pain	 in	 the	 previous	 year,	with	 pain	 and	 disability	 increasing	with	
age.22	Another	study	comparing	mild	HA	adults	with	age‐matched	
controls	 found	 the	maximum	 joint	 score	 to	 be	 significantly	 higher	
(worse)	in	mild	HA.26	Development	of	inhibitors	to	FVIII	in	mild	HA	
reached	a	cumulative	incidence	of	4.0%‐7.8%	over	10	years	in	two	
retrospective	cohort	studies	with	long‐term	follow‐up.8,12
3.6 | Quality of life
Patient‐reported	 outcomes	 were	 available	 in	 three	 studies,	 all	
of	 which	 were	 published	 in	 the	 past	 10	 years	 (Figure	 2).	 Each	
study	 used	 a	 different	 QoL	 instrument:	 the	 SF‐36,26	 SF‐123 and 
HAEMO‐QoL‐A.18	 SF‐36	general	 health	was	 lower	 for	mild	HA	vs	
age‐matched	 healthy	 controls	 in	 a	Canadian	 cohort	 (58.1	 vs	 70.8,	
P	<	0.05,	n	=	47).26	No	other	studies	reported	QoL	in	mild	HA	adults	
compared	to	healthy	controls	or	population	norms.
In	 a	 prospective	 US	 study,	 SF‐12	 physical	 component	 sum‐
mary	was	higher	(better	QoL)	for	mild	HA	compared	to	severe	HA	
(P	=	0.014,	n	=	42),	while	mental	component	summary	was	not	sig‐
nificantly	 different	 between	mild	 and	 severe	HA.3	No	differences	
between	severe	and	mild	HA	were	found	using	the	Haemo‐QOL‐A,	
in	a	small	UK	survey	study	reported	to	date	only	as	a	meeting	ab‐
stract.18	It	is	notable	that	this	study	required	long‐term	use	of	FVIII	
concentrate,	meaning	that	mild	HA	patients	in	this	study	were	prob‐
ably	not	representative	of	the	overall	mild	HA	population.
3.7 | Societal impacts
Societal	 impacts,	which	 should	 include	productivity	 loss,	disability	
and	time	lost	from	work/school,	were	mentioned	in	five	studies,	but	
were	not	often	quantified	 in	ways	that	would	allow	comparison	to	
populations	without	HA.	One	study	estimated	5	disability‐adjusted	
life	 years	 (DALYs)	 lost	 per	 case	 of	mild	HA,	 using	 a	modelling	 ap‐
proach	to	assess	 lifetime	burden	of	disease.16	Employment	of	mild	
HA	patients	was	60%	(27/45)	compared	to	68%	(21/31)	for	healthy	
controls	in	a	Canadian	cohort;	the	difference	did	not	reach	statistical	
significance.26	In	a	multicentre	US	study,	mild	HA	patients	missed	an	
average	of	6.2	work	days	per	year,	of	which	4.7	days	(76%)	were	due	
to	HA.3	Finally,	a	retrospective	study	in	Italy	noted	3.4	missed	days	
of	work	per	year,	with	no	benchmark	provided	for	patients	without	
HA.23	Table	4	summarizes	the	data	available	for	health	care	cost	and	
utilization	and	societal	impacts	(direct	and	indirect	costs	of	mild	HA).
TA B L E  1  Characteristics	of	included	studies
 
Number of 
studies
Number of 
mild HA adults
Total 17 3213
Country/sites   
Europe 10 1045
North	America 6 2049
Japan 1 119
Patient	population	of	entire	
studya
  
Mild	HA	adults	and	age‐
matched	healthy	controls
1 47
Mild/moderate	HA,	mild	HA/
HB
3 217
HA,	any	severity 5 122
HA	or	HB 5 2044
Various	coagulopathies 3 783
Year	of	publication   
1996‐2007b 2 56
2008‐2017 15 3157
Level	of	evidence/study	design   
IB	(Prospective	cohort	or	
registry)
6 1517
IIB	(Retrospective	cohort) 6 316
IIC	(Outcomes	research,	
survey	data)
5 1380
aData	were	extracted	for	the	subset	of	patients	of	interest	(mild	HA	
adults)	in	this	review.	
bSearch	dates	extended	back	to	1966	(the	initiation	of	MEDLINE	data‐
base),	but	the	earliest	study	meeting	eligibility	criteria	was	published	in	
1996. 
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3.8 | Health care cost and utilization
We	sought	details	on	health	care	utilization	 (clinic	visits,	hospitaliza‐
tion	days,	etc)	and	health	care	costs	(direct	costs)	 in	adults	with	mild	
HA;	while	such	costs	are	a	topic	of	discussion	in	recent	literature,	we	
found	they	were	generally	reported	for	HA	overall.	Mild	HA	health	care	
costs	were	reported	in	2	studies,	with	rather	different	health	care	set‐
tings:	a	2015	study	from	Portugal	reported	mean	costs	of	793€/year,	
36%	of	which	was	the	cost	of	clotting	factor.21	In	contrast,	a	US‐based	
study	conducted	in	1995	estimated	annual	costs	of	$22	182	for	mild	
HA,	81%	of	which	was	clotting	factor.15	Health	care	utilization	was	not	
reported	for	adults	with	mild	HA	in	any	of	the	studies	in	our	review.
4  | DISCUSSION
Limited	data	were	available	on	ABR	in	mild	HA	adults	 (three	stud‐
ies	meeting	our	eligibility	criteria,	 reporting	between	0.44	and	4.5	
mean	bleeding	episodes/year).8,25,28	Because	data	were	scarce	and	
estimates	varied,	we	consulted	studies	not	meeting	inclusion	criteria	
to	provide	context	 for	ABR.	Two	studies	were	 found	with	an	ABR	
estimate	for	mild	HA	patients	of	all	ages	(including	children);	mean	
ABR	centred	on	0.5‐0.6	episodes	per	year.29,30	Mild	HA	patients	in	
our	review	also	experienced	other	morbidity,	QoL	impacts	and	eco‐
nomic	impacts.
Quantifying	 outcomes	 for	 adult	 patients	with	mild	HA	 remain	
challenging,	with	estimates	of	 key	QoL	and	cost	data	often	based	
on	 small	 subsets	 of	 a	 single	 study.	One	 complicating	 factor	 is	 the	
definition	of	mild	HA	based	on	FVIII	levels,	which	can	fluctuate.	In	
general,	the	mild	HA	population	is	defined	as	patients	with	FVIII	lev‐
els	>5%	(or	5	IU/dL)	and	up	to	40%	(or	40	IU/dL).	However,	there	has	
been	occasional	variation	in	this	range,	as	shown	in	Table	2,	as	well	as	
in	a	recent	communication	from	the	Scientific	Subcommittee	(SSC)	
of	the	International	Society	of	Thrombosis	and	Haemostasis.31	Few	
studies	put	mild	HA	outcomes	in	the	context	of	population	norms;	
therefore,	the	clinical	impact	of	mild	HA	may	be	under‐represented	
TA B L E  2  Bleeding	episodes	reported	in	mild	HA	patients
Study
Population (FVIII level/
age) Follow‐up period
Bleeding events
% (n/N) of patients with bleeding episodes/pt year (SD)
Prospective	cohort	(US,	
Canada)12
6%‐40%	(median	NR)
Age	NR
5	y	(2002‐2006) 36%	(4/11)	had	bleeding	scorea	>0,	
indicating	at	least	one	bleeding	
episode	other	than	surgery,	dental	
procedures	and	major	accidents
NR
Cross‐sectional	survey	
(Finland)22
5%‐40%	(median	NR)
Age	≥16
1	y	(years	NR;	 
publication	1996)
40%	(8/20)	had	at	least	one	episode	
of	moderate	bleedingb; none had 
severe	bleeding
NR
Retrospective	cohort	
(Italy)8
0.6‐0.33	IU/mL	(me‐
dian	0.15	IU/mL)
Median	age	35	(range	
3‐88)c
10	y	(range	1‐39;	
1985‐2010)
91%	(68/75)	had	at	least	one	bleed	
during	follow‐upc:	27%	joint,	35%	
muscle,	73%	muco‐cutaneous,	13%	
postoperative,	21%	after	dental	work
0.56	(0.67)
Includes	all	bleeds	re‐
gardless	of	treatment
Retrospective	cohort	
(Slovenia)25
5%‐40%	(mean	8.5%)
Age	13‐54
6	y	(2007‐2014) 57%	(8/14) 
Includes	surgery,	trauma,	dental	
procedures
0.44d
Includes	all	bleeds	re‐
gardless	of	treatment
Retrospective	cohort	
(Canada)26 e
5%‐40%	(mean	
0.15	IU/mL)
Adults	≥18	(mean	age	
46)
5	y	(year	NR;	 
publication	2008)
17%	(8/46)	with	2	or	more	bleeds	
requiring	medical	assessment	or	
therapy	in	past	5	y
NR
Prospective	cohort	
(Italy)27
NR	(median	NR)
Adults	≥18
Duration	NR	
(2011‐2013)
5.5%	(1/18)	had	evidence	of	cerebral	
microbleedf
NR
Prospective	cohort	
(US)3,20,28g
6%‐30%	(median	NR)
Adults	≥18
2	y	(2005‐2007) NR	(23	patients	with	data) 4.5	(10.0)
Definition	of	bleeding	
episodes	not	available
Abbreviation:	NR,	not	reported.
aBleeding	score	calculated	from	5	y	mean	scores	of	haemarthrosis	and	soft	tissue	haematoma.	
bBleeding	histories	were	divided	into	severity	based	on	symptom	clustering	across	the	whole	cohort	of	coagulation	disorders	(n	=	224);	most	epi‐
sodes	were	joint	and	soft	tissue	bleeds.	
cOutcomes	may	include	some	patients	under	13	y;	study	was	retained	due	to	long	follow‐up	duration	and	detailed	reporting.	Three	patients	had	FVIII	
inhibitors.	
dEleven	soft	tissue	bleeds	occurred	in	one	patient	who	developed	FVIII	inhibitors.	
eSubjects	are	from	large	kindred	with	specific	mutation	(VAL2016ala).	
fPatients	without	prior	symptomatic	brain	bleeding	were	assessed	for	evidence	of	asymptomatic	bleeding	using	cerebral	MRI.	
gThis	analysis	of	HUGS‐Va	included	only	participants	with	complete	follow‐up	data.	
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and	unmet	needs	remain	unaddressed.	While	mean	ABRs	were	rela‐
tively	low,	mild	HA	had	measurable	impact	on	QoL	and	represents	an	
area	of	therapeutic	concern	requiring	further	study.	Until	recently,	
treatment	 goals	 in	 haemophilia	 were	 FVIII	 trough	 levels	 of	 >1%,	
to	 prevent	 major	 bleeding.	With	 the	 advent	 of	 extended	 half‐life	
FVIII	 concentrates	 and	 novel	 non‐replacement	 therapies,	 and	 the	
TA B L E  3   Joint	score	and	pain	reported	in	mild	HA	patients
Study
Population (FVIII 
level/age) Follow‐up period
Number 
of mild HA 
patients
Mean (SD) or Median (range)
Joint score (name of 
scale)
Pain or overall severity 
score (name of scale)
Prospective	cohort	
(US)3,20,28a
6%‐30%	(median	NR)
Age	≥18
2	y	(2005‐2007) 23 Joint	range	of	motion	
limitation	(AAOS):	
5.4	±	4.5
NR
Cross‐sectional	survey	
(Finland)22
5%‐40%	(median	NR)
Age	≥16
1	y	(years	NR,	
publication	1996)
20 NR Pain	in	previous	year:	5%	
(1/20)	severe,	15%	(3/20)	
moderateb
Retrospective	cohort	
(Italy)8
0.06‐0.33	IU/mL	
(median	0.15	IU/mL)
Median	age	35	
(range	3‐88)c
10	y	(range	1‐39)	
(1985‐2010)
75 Mean	physical	joint	
score	0.88	±	1.78	(scale	
NR)
NR
Retrospective	cohort	
(Canada)26d
5%‐40%	(mean	
0.15	IU/mL)
Age	≥18	(mean	age	
46)
5	y	(year	NR,	pub‐
lication	2008)
47 Max	joint	score	by	
Colorado	PE0.5:	5.3	
mild	haemophilia	vs	2.8	
control	(P	<	0.05)
HAQ	pain	score:	0.51	hae‐
mophilia	vs	0.61	controls	
(no	significant	difference)
Abbreviations:	AAOS,	American	Academy	of	Orthopaedic	Surgeons;	Colorado	PE0.5:	Scale	based	on	modified	World	Federation	of	Haemophilia	
(WFH)	Physical	Joint	Examination	instrument.19;	NR,	not	reported.
aThis	analysis	of	HUGS‐Va	included	only	participants	with	complete	follow‐up	data.	
bPain	and	disability	increased	with	age.	
cOutcomes	may	include	some	patients	under	13	y;	study	was	retained	due	to	long	follow‐up	duration	and	detailed	outcome	reporting.	
dSubjects	are	from	large	kindred	with	specific	mutation	(VAL2016ala).	Normative	data	are	from	age‐matched	healthy	controls	(n	=	32).	
F I G U R E  2  Quality	of	life	scores	in	mild	HA	(as	%	of	maximum	score).	§	Physical	component	summary	(PCS)	and	mental	component	
summary	(MCS)	for	SF‐36	and	SF‐12	use	norm‐referenced	scoring	(not	available	as	transformed/scaled	scores)	and	are	shown	as	%	of	the	
closest	available	age	and	country	norms.	For	HUGS‐Va,	normative	data	were	not	reported	within	the	study,	so	SF‐12	norms	for	Utah,	age	
>18	were	used.21 * P	<	0.05	vs	comparison
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potential	 for	 gene	 therapies,	 understanding	 around	 target	 trough	
levels	is	evolving	to	suggest	there	may	be	additional	benefit	in	tar‐
geting	non‐haemophilia	levels	(ie	>40%),	as	opposed	to	levels	within	
the	mild	HA	range.	Such	targets	may	be	achievable	through	recent	
therapeutic	advances	 such	as	 those	 in	adeno‐associated	viral	 vec‐
tor‐mediated	gene	therapy,	which	may	enable	sustained	expression	
of	FVIII	activity	following	a	one‐time	infusion.32	We	would	need	to	
consider	currently	unmeasured,	cumulative	benefits	to	those	living	
with	mild	HA.	This	review	should	be	followed	by	further	prospective	
studies	to	understand	the	need	of	all	patients	with	mild	haemophilia.
Strengths	of	this	systematic	review	include	the	comprehensive	
search	and	rigorous	methodology	including	a	prospective	plan,	using	
current	best	practices	 for	 systematic	 literature	 review.	Limitations	
relate	 primarily	 to	 the	 availability	 and	 comparability	 of	 published	
evidence.	Data	 on	mild	HA	 adults	 are	 frequently	 aggregated	with	
moderate	HA,	mild	haemophilia	B	and/or	mild	HA	paediatric	patients	
in	the	published	literature.	Despite	our	efforts	to	extract	clinical	and	
humanistic	 outcomes	 data	 for	 comparable	 populations	 (mild	 HA	
adults),	meta‐analysis	was	ultimately	not	feasible	due	to	variability	in	
reporting.	Studies	used	different	measures,	scales	and	time	points,	
with	too	few	studies	using	consistent	formats.	The	body	of	evidence	
in	mild	HA	 is	also	 limited	by	missing	data	and	selective	availability	
of	outcomes,	making	it	difficult	to	gain	a	comprehensive	picture	of	
disease	burden	across	all	outcomes	of	interest.
This	review	has	revealed	a	lack	of	evidence	in	the	specific	popu‐
lation	of	mild	HA	adults;	evidence	is	low	quality	in	part	because	data	
had	to	be	separated	out	for	the	population	of	interest.	Considering	
the	limitations	of	the	current	body	of	evidence,	higher	quality	studies	
in	this	area	are	needed.	Such	studies	would	report	both	bleeding	and	
other	clinical	outcomes	based	on	common	definitions	and	for	a	rep‐
resentative	population	of	mild	HA	adults.	Areas	for	further	research	
include	more	 robust	comparison	 to	healthy	controls	or	population	
norms,	especially	for	QoL	and	other	patient‐reported	outcomes.	A	
recent	multi‐stakeholder	effort	to	define	core	outcomes	for	trials	in	
haemophilia	highlighted	the	importance	of	mental	health	outcomes;	
this	is	an	area	where	existing	published	evidence	for	mild	HA	adults	
is	lacking.33
5  | CONCLUSION
To	the	best	of	our	knowledge,	this	is	the	first	systematic	review	to	
assess	available	evidence	of	clinical	risks	and	societal/economic	im‐
pacts	of	disease	in	adult	patients	with	mild	HA.	Based	on	our	review,	
data	 from	 adult	 patients	 with	mild	 HA	 are	 frequently	 aggregated	
with	 other	 types	 of	 haemophilia	 in	 the	 published	 literature.	 Few	
studies	to	date	have	focused	on	this	population	alone,	nor	have	many	
authors	described	mild	HA	outcomes	 in	 the	context	of	population	
norms.	While	mean	ABRs	were	 relatively	 low,	mild	HA	had	meas‐
urable	 impact	on	QoL	and	productivity	 and	 represents	 an	 area	of	
therapeutic	need	requiring	further	study.
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